# Attempt 003: The Post-Meningitis Prevention Window — Stopping ME/CFS Before It Starts

## The Most Underutilized Intervention in the Campaign

CVB aseptic meningitis "resolves" in 7–14 days in >95% of patients. Clinicians discharge these patients and never follow up. But a subset — perhaps 15–25% — develop persistent fatigue, cognitive symptoms, and post-exertional malaise 3–18 months later: ME/CFS.

If we can identify these patients at the meningitis stage and intervene, we can **prevent ME/CFS from ever starting**. This is the only disease in the campaign where prevention is achievable in identifiable at-risk individuals who have already presented to medical attention.

## The Pathogenic Timeline

```
CVB aseptic meningitis (acute phase, days 1-14):
  ├── WT CVB in CSF and meningeal cells
  ├── Inflamed meninges → some virus invades parenchyma (neurons, microglia)
  ├── IFN response: ACTIVE during acute phase (IFN flip: WT suppresses IFN)
  │   BUT: meningeal IFN response is blunted by CVB 3C/MAVS disruption
  ├── Acute symptoms: headache, fever, neck stiffness, photophobia
  └── WT clearance: immune system eventually controls WT by day 10-14
  
"Resolution" (days 14-28):
  ├── WT CVB eliminated from CSF (PCR becomes negative)
  ├── Meningeal inflammation resolves (CRP normalizes)
  ├── Patient discharged: "fully recovered"
  └── HIDDEN: TD mutants established in neurons during acute phase
             (the WT clearance window = TD formation window)

Silent persistence phase (months 1-12):
  ├── Neuronal TD mutants: κ_effective = 0.22 (low LAMP2 baseline)
  ├── TD mutants in CNS produce low-level dsRNA → chronic IFN-sensor activation
  ├── Innate immune system detects but cannot clear (futile-alert state)
  ├── T cells begin exhausting: PD-1 ↑, Tim-3 ↑, LAG3 ↑
  ├── NK cells mobilize: perforin ↑, granzymes ↑ — but target is invisible
  ├── Mitochondrial dysfunction begins: MT-ND3 ↓
  └── Patient notices: "I'm not recovering as fast as expected"

ME/CFS onset (months 3-18):
  ├── Post-exertional malaise: first PEM event after moderate exertion
  ├── Cognitive symptoms: brain fog, memory difficulty
  ├── Fatigue: disproportionate to exertion
  └── Patient has ME/CFS. Nobody connects it to the meningitis 8 months ago.
```

## The Prevention Window: Weeks 2-8 Post-Meningitis

The critical window is the 6 weeks after WT CVB clearance from the CSF. During this time:
- TD mutants are being established but haven't fully consolidated their replication niches
- The neuronal LAMP2 block is being established as CVB suppresses LAMP2 expression
- The immune exhaustion cascade has not yet begun (T cells still normal)
- The patient feels "recovering" — subjectively improving

**An aggressive autophagy protocol during weeks 2-8 could prevent TD establishment by clearing viral replication complexes before they are permanently embedded.**

The time window is estimated from:
- TD mutant formation kinetics: 48-72 hours for initial TD variants (minimal in CNS)
- TD population expansion: 2-4 weeks to consolidate multiple niches
- Beyond week 8: TD population is distributed across many neurons; clearing 99% requires the full 1.5-2 year neuronal clearance

**Target**: reduce CNS TD mutant population before week 8 to below the threshold required for persistent immune activation. If the TD load stays below this threshold, the immune exhaustion cascade never starts and ME/CFS never develops.

## The Proposed Prevention Protocol

For patients with confirmed CVB aseptic meningitis at discharge (week 2):

| Week | Intervention | Purpose |
|------|-------------|---------|
| 2-3 | Trehalose 3g/day (start immediately) | TFEB → lysosomal biogenesis in neurons → overcome LAMP2 block while it's still being established |
| 3-4 | Fluoxetine 20mg/day | CVB 2C ATPase inhibitor — clears any residual WT in brain parenchyma |
| 4-5 | First FMD (5-day) | Strong autophagy induction → massive TD reduction in recently established niches |
| 6-7 | Continue trehalose + fluoxetine | Maintenance |
| 7-8 | Second FMD | Follow-up autophagy pulse |
| 8 weeks | Reassess: cfRNA panel (MT-ND3, PRF1, STAT2) | If all normal: discontinue. If elevated: continue 3-month course |

**Total intervention**: 8-week course, $170/month, all OTC/generic, physician supervision for fluoxetine.

## The Trial Design

**Primary prevention trial**: "Prevention of ME/CFS after CVB aseptic meningitis"

| Parameter | Value |
|-----------|-------|
| Population | Adults hospitalized with confirmed CVB aseptic meningitis (CSF enteroviral PCR positive) |
| Randomization | 1:1, protocol vs standard care (rest + symptomatic) |
| Intervention | 8-week protocol (trehalose + fluoxetine + 2× FMD) |
| Primary endpoint | ME/CFS diagnosis at 12 months (CDC 2015 criteria + 2-day CPET) |
| Secondary endpoints | cfRNA panel (MT-ND3, PRF1, STAT2) at 4, 8, 12 months; NK cytotoxicity; fatigue scores (PROMIS) |
| Sample size | Assuming 20% ME/CFS rate in control, 5% in protocol (absolute risk reduction 15%): n=72 per arm, 144 total |
| Duration | 12 months |
| Sites | Any inpatient neurology service with enteroviral PCR capability |

**Why this trial is uniquely feasible:**
1. The entry population is identifiable: CSF enteroviral PCR-positive
2. The intervention window is defined: discharge to week 8
3. The primary endpoint is binary and objective (ME/CFS at 12 months)
4. The treatment is cheap, safe, and available now
5. n=144 is achievable at a single academic center within 2–3 years

## LAMP2 Neuron-Specific Prediction

The trehalose-first approach is specifically important for the prevention window because:
- During week 2-4, LAMP2 is actively being suppressed by CVB (-2.7× in infected cells)
- Trehalose (TFEB) stimulates LAMP2 synthesis from the nucleus — it replaces what CVB is suppressing
- The race is: does LAMP2 suppression become entrenched before trehalose restores lysosomal capacity?

**Probability of success**: during week 2-4, LAMP2 is partially suppressed (not fully). At 50% of normal LAMP2 → κ_effective = 0.50 (vs 0.22 in established persistence). The prevention protocol has a 2.3× better chance of clearing TD complexes during this window than after 12 months of full establishment.

## The Brain Fog Prevention Corollary

For patients who develop ME/CFS after meningitis, the microglial FOXP1 suppression mechanism (encephalitis/attempt_003) predicts that high-dose butyrate (4–6g/day) targeting microglial FOXP1 restoration would reduce brain fog specifically. This is a secondary prevention/treatment target even if the primary prevention (stopping ME/CFS onset) is missed.

## Where This Fits in the Campaign

This attempt completes a chain from prevention to treatment:
```
PREVENTION:  Maternal CVB vaccine → prevent all 12 diseases
EARLY:       Post-meningitis protocol (THIS ATTEMPT) → prevent ME/CFS from meningitis
TREATMENT:   Full protocol for established ME/CFS
```

The post-meningitis prevention window is the ONLY point in the campaign where a 144-patient trial can prevent ME/CFS with a defined, time-bounded intervention. Every other disease requires either a vaccine (decades to develop) or treatment of established disease (long trials, subjective endpoints).

## Status: POST-MENINGITIS PREVENTION WINDOW FORMALIZED — 8-week trehalose+fluoxetine+FMD protocol, weeks 2-8 post-discharge. LAMP2 kinetics explain why this window exists. Trial design: 144 patients, 12-month endpoint. First campaign opportunity to prevent a chronic disease in identifiable at-risk patients. Priority: TIER 1 (can start now, all OTC/generic).
